Please find enclosed

October 28, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Outcome of Board Meeting Ref: Regulation 30, 33 of SEBI Listing Regulations We wish to inform you that the Board of Directors at their meeting held today i.e. Wednesday, October 28, 2026 have inter-alia considered and approved the following: 1. The Unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, basis recommendation of the Audit Committee alongwith the Limited Review Report on the Financial Results (Standalone and Consolidated) for the quarter and half ended September 30, 2026. In this regard, we enclose: 1. Statement of Financial Results i.e. Profit & Loss 2. Statement of Assets and Liabilities 3. Statement of Cash flows 4. Limited Review Report by the Statutory Auditors The said Unaudited Financial Results are also being uploaded on the Company's website www.aartipharmalabs.com as required under Regulation 46 of the Listing Regulations. 2. Noted and taken on record, the resignation of Shri. Piyush Lakhani from the position of Chief Financial Officer (CFO) and Key Managerial Personnel of the Company to pursue an alternate career opportunity outside the organization. He will be relieved from the services of the Company with effect from the close of business hours on October 30, 2026. The resignation letter received from Shri. Piyush Lakhani is enclosed herewith as “Annexure – B”. 3. Appointment of Smt. Vibha Thakkar as the Chief Financial Officer (CFO) and Key Managerial Personnel of the Company w.e.f October 31, 2026 upon the recommendation of the Nomination and Remuneration Committee and Audit Committee. The disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as “Annexure – A”. The above information is being made available on the Company’s website at www.aartipharmalabs.com The meeting of the Board of Directors commenced at 2:00 p.m. and concluded at 7:10 p.m. Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl: a/a “Annexure – A” SR. Particulars Disclosure Shri Piyush Lakhani Smt. Vibha Thakkar 1 Reason for change viz. Resignation from the Appointment of Smt. Vibha Thakkar appointment, resignation, re- position of Chief as the Chief Financial Officer (CFO) appointment, removal, death Financial Officer and Key Managerial Personnel of or otherwise and Key Managerial the Company w.e.f October 31, Personnel of the 2026. Company to pursue an alternate career opportunity outside the organization. 2 Date of He will be relieved October 31, 2026 appointment/reappointment/ from the services of cessation (as applicable) & the Company with term of appointment/ re- effect from the close appointment of business hours on October 30, 2026. 3 Brief profile Not Applicable Smt. Vibha Thakkar is a qualified (In case of Appointment) Chartered Accountant from the Institute of Chartered Accountants of India (ICAI). She has over 18 years of rich and progressive experience across finance functions in diverse industry verticals including Speciality chemicals, FMCG, Automotive, Pharmaceuticals and Big4 consultings. She most recently served as AVP- Finance & Accounts at NOCIL Limited. Prior to that she held senior leadership and key financial roles at renowned organizations including VIP Industries Limited, Greaves Cotton Limited, Sandoz Private Limited, KPMG. She holds a Bachelors Degree in Commerce and has completed the General Management Program from the Indian School of Business (ISB). She was also featured under the ‘40 Under 40’ category by Tradeflock in 2025. 4 Disclosure of relationships Not Applicable Not Applicable between directors (in case of appointment of a director) gokhale & sathe LLP chartered accountants (formerly known as gokhale & sathe) INDIA 304/308/309/31 1,udyog mandir no.1, 7-c, bhagoji keer marg,mahim, mumbai - 400 016,maharashtra,india. Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Aarti Pharmalabs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Aarti Pharmalabs Limited Fs We have reviewed the accompanying Statement of unaudited standalone financial results of Aarti Pharmalabs Limited (“the Company”) for the quarter ended 30 September 2026 and the year to date results for the period from 1 April 2026 to 30 September 2026 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Listing Regulations”). DZ This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Tel.(off). : +91 022 4348 4242 | Email : office@gokhalesathe.in | Website : www.gokhalesathe.com Cx gokhale & sathe LLP chartered accountants “INDIA (formerly known as gokhale & sathe) Emphasis of Matter Se We draw attention to the following matters: (a) Note 3 to the Statement, which describes the order dated 29 August 2026 of the Collector and Additional Superintendent of Stamps, Gandhinagar, determining stamp duty of Rs. 2,500.00 lakhs and levying penaltie [Showing first 8,000 characters — download PDF for full document]